Aurinia Pharmaceuticals - Common Shares (AUPH) closed at $15.48 on November 16, 2026, down 1.6% from the previous close, on volume of 855,870 shares (30-day average 843,394).
Data as of November 16, 2026.
16-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the largest for 5, 30, 60 and 90 days
Aurinia raises 2026 revenue outlook as LUPKYNIS sales and operating cash flow grow
Market Chameleon (Fri, 30-Oct 4:26 AM ET)
Business Wire (Fri, 30-Oct 8:00 AM ET)
Aurinia’s Patent Settlement with Teva Secures Voclosporin Exclusivity Until 2036
Market Chameleon (Thu, 20-Aug 5:42 AM ET)
Aurinia Settles Patent Litigation with Teva
Business Wire (Wed, 19-Aug 4:05 PM ET)
Market Chameleon (Thu, 7-May 5:18 AM ET)
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Aurinia Pharmaceuticals - Common Shares trades on the NASDAQ stock market under the symbol AUPH.
As of November 16, 2026, AUPH stock price declined to $15.48 with 855,870 million shares trading.
AUPH has a beta of 0.05, meaning it tends to be less sensitive to market movements. AUPH has a correlation of 0.00 to the broad based SPY ETF.
AUPH has a market cap of $2.07 billion. This is considered a Mid Cap stock.
Last quarter Aurinia Pharmaceuticals - Common Shares reported $84 million in Revenue and $.23 earnings per share. This fell short of revenue expectation by $-627,264 and exceeded earnings estimates by $.01.
In the last 3 years, AUPH traded as high as $19.25 and as low as $4.71.
The top ETF exchange traded funds that AUPH belongs to (by Net Assets): IWM, IWO, IBB, VTWO, FESM.
AUPH has underperformed the market in the last year with a price return of +1.7% while the SPY ETF gained +11.2%. However, in the short term, AUPH had mixed performance relative to the market. It has outperformed in the last 3 months, returning +2.0% vs -4.6% return in SPY. But in the last 2 weeks, AUPH shares have been beat by the market, returning -7.0% compared to an SPY return of -2.1%.
AUPH support price is $15.38 and resistance is $16.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AUPH shares will trade within this expected range on the day.